Jeremy Teoh presents a tour de force on how to optimize TURBT in management of patients with bladder cancer including techniques such as EBRT and Robotic TUR.
@jteoh_hk #GU26
@IBCG_BladderCA
It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs.
This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT.
And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT.
Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression.
If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics.
This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26
@UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi
Feb 27, 2026 · 6:27 PM UTC
Great talk from @jteoh_hk ! An elegant balance between surgical technique and outcome data to fit with multidisciplinary audience 👏🏾👏🏾👏🏻
